Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: An Italian multicenter experience

Journal of Hepatology

Volumn 33, Issue 3, 2000, Pages 448-455

  Barbaro, Giuseppe ^a,e   Lorenzo, Gabriella Di ^a   Soldini, Maurizio ^a   Giancaspro, Giuseppe ^a   Pellicelli, Adriano ^b   Grisorio, Benvenuto ^c   Barbarini, Giorgio ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c GENERAL HOSPITAL   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e NONE   (Italy)

Author keywords

Chronic hepatitis C; Interferon alpha; Naive; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033841034     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80281-0     Document Type: Article

References (21)

1. Therapy of hepatitis C: A meta-analysis of interferon alpha-2b trials
2. Ribavirin treatment for chronic hepatitis C
3. A pilot study of ribavirin therapy for chronic hepatitis C
4. Hepatitis C viral RNA titers in serum prior to, during and after oral treatment with ribavirin for chronic hepatitis C
5. The effect of interferon alpha and ribavirin combination therapy in naive patients with chronic hepatitis C
6. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
7. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy group
8. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
9. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
10. Interferon alpha-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon alpha alone: An Italian multicenter, randomized, controlled, clinical study
11. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
12. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources
13. Characterization of the genomic sequence of the type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection
14. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
15. The treatment of chronic viral hepatitis
16. Molecular mechanisms of action of ribavirin
17. Combined interferon alpha-2, rimantidine hydrochloride and ribavirin inhibition of influenza virus replication in vitro
18. Predictors of response to interferon therapy
19. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon alpha-therapy
20. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon